Zohydro's greater abuse potential, lack of deterrence concerns US FDA
This article was originally published in Scrip
Executive Summary
If approved and marketed, Zogenix's extended-release single-entity hydrocodone analgesic Zohydro ER will be abused, possibly at a rate greater than that of currently available hydrocodone combination products, US FDA drug reviewers concluded after examining the application for the experimental medicine.